| Author: | ISBN: | 9781608051366 | |
| Publisher: | Bentham Science Publishers | Publication: | July 31, 2013 |
| Imprint: | Bentham eBooks | Language: | English |
| Author: | |
| ISBN: | 9781608051366 |
| Publisher: | Bentham Science Publishers |
| Publication: | July 31, 2013 |
| Imprint: | Bentham eBooks |
| Language: | English |
This is the second volume of the Patent eBook Series titled Topics in Anti-Cancer Research. The eBook includes updated chapters on topics relevant to contemporary cancer research published in the journal, Recent Patents on Anti-Cancer Drug Discovery. This volume covers scientific and patented novel chemotherapeutic agents and drugs for metastatic castration-resistant prostate cancer and Ras/ Raf /MEK/ERK pathway, P1K, AKT and mTORC1/2 inhibitors, ATPase inhibitors for cancer therapy, and sphingomyelin biosynthesis which regulates cancer cell death and growth. Other chapters also explain research on biochemical regulation i.e. cell cycle and energy metabolism, the role of genetic variations of FcγRs gamma receptors in monoclonal antibody based anti-cancer therapy and effectiveness of antiangiogenic therapy, endogenous angiogenesis inhibitors and anti-angiogenic drugs for the treatment of renal cell carcinoma, prevention of cancer by ribonucleotide reductase, anticancer activity of Erlotinib in glioblastoma and the mechanisms of action of nanodrugs and nano-sized camptothecin drugs in cancer chemotherapy. The volume also covers recent studies in the field of on conutrition. The broad range of topics covered in this second volume will be of immense interest to clinicians, scientists and R&D experts seeking new targets for the prevention of cancer, novel oncogenic biomarkers, and methods for cancer therapy.
This is the second volume of the Patent eBook Series titled Topics in Anti-Cancer Research. The eBook includes updated chapters on topics relevant to contemporary cancer research published in the journal, Recent Patents on Anti-Cancer Drug Discovery. This volume covers scientific and patented novel chemotherapeutic agents and drugs for metastatic castration-resistant prostate cancer and Ras/ Raf /MEK/ERK pathway, P1K, AKT and mTORC1/2 inhibitors, ATPase inhibitors for cancer therapy, and sphingomyelin biosynthesis which regulates cancer cell death and growth. Other chapters also explain research on biochemical regulation i.e. cell cycle and energy metabolism, the role of genetic variations of FcγRs gamma receptors in monoclonal antibody based anti-cancer therapy and effectiveness of antiangiogenic therapy, endogenous angiogenesis inhibitors and anti-angiogenic drugs for the treatment of renal cell carcinoma, prevention of cancer by ribonucleotide reductase, anticancer activity of Erlotinib in glioblastoma and the mechanisms of action of nanodrugs and nano-sized camptothecin drugs in cancer chemotherapy. The volume also covers recent studies in the field of on conutrition. The broad range of topics covered in this second volume will be of immense interest to clinicians, scientists and R&D experts seeking new targets for the prevention of cancer, novel oncogenic biomarkers, and methods for cancer therapy.
